Donepezil Tablet
Product Images NDC 70518-4380

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil (NDC 70518-4380). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezilfigure10 (Donepezilfigure10)

A line graph comparing the cumulative percentage of patients against ADCS-ADL change from baseline between Donepezil Hydrochloride 10 mg/day and placebo groups. The graph shows patient response curves with Donepezil and placebo plotted distinctly, highlighting differences in functional change distribution over a range from -20 to 20.*

FDA Label Image

Donepezilfigure8 (Donepezilfigure8)

A cumulative percentage graph depicting the change from baseline in SIB scores comparing Donepezil hydrochloride 10 mg/day versus placebo. The x-axis represents SIB Change from Baseline, ranging from +30 to -75, and the y-axis indicates the cumulative percentage of patients, ranging from 0 to 100%. Two curves show patient response differences between the treatment and placebo groups.*

FDA Label Image

Figure1 (Figure1)

A line graph depicting the ADAS-cog change from baseline (mean ± SE) over 24 weeks of drug treatment and 6 weeks of placebo. The graph compares Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo groups, showing trends in clinical improvement and decline across the treatment period.*

FDA Label Image

Figure2 (Figure2)

A cumulative percentage plot showing patients' change from baseline on an ADAS cognitive scale for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The x-axis represents change from baseline, while the y-axis shows cumulative percentage of patients. A table summarizes treatment group response rates at different change thresholds.*

FDA Label Image

Figure3 (Figure3)

A bar chart displaying CIBIC-Plus ratings categorized as markedly improved, improved, minimally improved, no change, minimally worse, moderately worse, and markedly worse. The graph compares percentages of patients across three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo.*

FDA Label Image

Figure4 (Figure4)

A line graph showing the change from baseline in ADAS-cog scores over 15 weeks of drug treatment with Donepezil hydrochloride 5 mg/day, 10 mg/day, and placebo. The graph illustrates clinical improvement or decline, with weekly intervals and error bars for data points.*

FDA Label Image

Figure5 (Figure5)

A cumulative percentage of patients graph showing change from baseline versus change in ADAS cognitive score for three treatment groups: donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The chart includes points labeled 7 points, 4 points, and no change, with percentages of patients achieving these changes indicated in a small table.*

FDA Label Image

Figure6 (Figure6)

A bar chart depicting percentages of patients by CIBIC-plus Rating categories, comparing Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The categories range from Markedly Improved to Markedly Worse, showing distribution of patient responses across treatment and placebo groups.*

FDA Label Image

Figure7 (Figure7)

Line graph showing the change in SIB scores from baseline over 6 months of treatment with Donepezil Hydrochloride 10 mg/day compared to placebo. The graph indicates clinical improvement or decline, with Donepezil showing an upward trend and placebo a downward trend over time.*

FDA Label Image

Figure9 (Figure9)

A line graph depicting clinical improvement or decline over 6 months of drug treatment. The y-axis represents ADCSD-ADL change from baseline (mean ± SE), ranging from -4 to 4, with baseline marked at zero. Two treatment lines are shown: Donepezil Hydrochloride 10 mg/day, which shows less clinical decline over time, and placebo, which shows greater decline.*

FDA Label Image

Remedy_label (Remedy Label)

Donepezil HCl Tablet C-III 5 mg oral tablets, 90 count, repackaged by RemedyRepack Inc. The label includes storage instructions (20-25°C), cautions on drug transfer restriction, and manufacturer information (Camber Pharma, Piscataway, NJ). Tablets are round white.*

FDA Label Image

Donepezilfigure11 (Donepezilfigure11)

Line graph showing SIB change from baseline (LS mean ± SE) over 24 weeks of drug treatment for Donepezil Hydrochloride at doses of 23 mg/day and 10 mg/day. The x-axis represents weeks of treatment, and the y-axis shows the SIB change, with clinical improvement above baseline and clinical decline below. The 23 mg/day dose shows higher SIB improvement compared to the 10 mg/day dose throughout the treatment period.*

FDA Label Image

Donepezilfigure12 (Donepezilfigure12)

A cumulative percentage of patients graph showing SIB change from baseline on the x-axis and cumulative percentage of patients on the y-axis. It compares two Donepezil hydrochloride dosages: 23 mg/day (diamonds) and 10 mg/day (circles), illustrating patient response distributions across these dosages.*

FDA Label Image

Donepezilfigure13 (Donepezilfigure13)

A bar graph displaying the distribution of patients by CIBIC-plus rating for Donepezil Hydrochloride at 23 mg/day (black bars) and 10 mg/day (white bars). The x-axis shows categories from Markedly Improved to Markedly Worse, and the y-axis indicates the percentage of patients ranging from 0 to 50 percent.*

FDA Label Image

Structure (Structure)

Chemical structure of donepezil hydrochloride, the active ingredient in Donepezil 5 mg tablets by RemedyRepack Inc. The diagram shows the molecular arrangement including methoxy groups, a piperidine ring, and a phenyl substituent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.